ERBB2 and breast carcinoma: A high expression of AEG-1 correlated with a poor prognosis of locally advanced human epidermal growth factor receptor 2 (HER-2) positive breast cancer patients after treatment with neoadjuvant chemotherapy and trastuzumab, suggesting a potential role of AEG-1 in conferring trastuzumab resistance [222].